Gilead and Galapagos's filgotinib shows sustained efficacy in ulcerative colitis study

Gilead and Galapagos's filgotinib shows sustained efficacy in ulcerative colitis study

Source: 
Seeking Alpha
snippet: 

Additional data from Phase 2b/3 Selection trial evaluating filgotinib in 1,348 biologic-naïve or biologic-experienced for the treatment of moderate to severe active ulcerative colitis (UC) patients, demonstrated sustained efficacy and safety. Results were presented at the 2020 United European Gastroenterology Week Virtual Meeting.